IGA NEPHROPATHY

This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease: FSGS, minimal change disease, and IgA nephropathy. Participants take the drug twice daily for a year to see if it reduces protein in the urine and is safe. The drug works on immu…

This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…

This study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney function decline in people with IgA nephropathy (Berger's disease). About 334 adults with biopsy-confirmed IgA nephropathy and high protein in their urine will receive either hydroxychloro…

This study tests whether combining budesonide and ambrisentan can reduce protein leakage in urine and slow kidney function decline in people with IgA nephropathy, a chronic kidney disease. About 129 adults with mild to moderate kidney impairment will receive both drugs for 36 wee…

This study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…

This early-stage study tests whether a new drug called BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 adults with confirmed IgA nephropathy will receive the drug and be monitored for side effects. The main goal is to check safety, not y…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This study looks at whether continuing TARPEYO (budesonide) for up to 19 months helps adults with IgA nephropathy, a kidney disease. Participants have already taken the drug for 9 months. Researchers will check urine and blood tests to see if the drug keeps working safely. About …

This program provides access to EXV811, atrasentan for people with IgA nephropathy, a serious kidney disease. It is for patients who have no other treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard therapies are not available.

This observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard …

This study follows 2000 people with IgA nephropathy who still have good kidney function. Researchers will test blood and urine samples to find biomarkers that might predict if and when kidney disease gets worse. The goal is to better understand the disease, not to test a new trea…